PRELUDE:Study to Investigate the Prevention of Relapse in Lymphoma Using Daily Enzastaurin

NCT00332202 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

758

Enrollment

INDUSTRY

Sponsor class

Conditions

Non Hodgkin Lymphoma

Interventions

DRUG: enzastaurin
DRUG: placebo

Sponsor

Eli Lilly and Company